Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery

被引:6
作者
Gaynutdinov, TI
Myshkin, E
Backer, JM
Backer, MV [1 ]
机构
[1] SibTech Inc, Newington, CT 06111 USA
[2] Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA
来源
PROTEIN ENGINEERING | 2003年 / 16卷 / 10期
关键词
adapter protein; chimeric RNase; delivery complexes; targeting drugs;
D O I
10.1093/protein/gzg097
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Assembled modular complexes for targeted drug delivery can be based on strong non-covalent interactions between a cargo module containing an adapter protein and a docking tag fused to a targeting protein. We have recently constructed a completely humanized adapter/docking tag system based on interactions between 15 amino acid (Hu-tag) and 110 amino acid (HuS) fragments of human ribonuclease I (RNase I). Although recombinant HuS can be expressed and refolded into a functionally active form, the purification procedure is cumbersome and expensive, and more importantly, it yields a significant proportion of improperly folded proteins. Here we describe engineering, high-yield expression, and purification of a chimeric bovine/human RNase (BH-RNase) comprising 1-29 N-terminal amino acids of bovine ribonuclease A and 30-127 amino acids of human RNase I. Unlike RNase I, the chimeric BH-RNase can be cleaved by either subtilisin or proteinase K between A20 and S21, providing a functionally active HuS. The HuS obtained from chimeric BH-RNase differs from wild-type HuS by an N24T substitution; therefore, we have reverted this substitution by mutating N24 to T24 in BH-RNase. This BH-RNase mutant can also be cleaved by subtilisin or proteinase K yielding wild-type HuS. The affinity of HuS obtained from BH-RNase to Hu-tag is approximately five times higher than that for recombinant HuS, reflecting a higher percentage of properly folded proteins.
引用
收藏
页码:771 / 775
页数:5
相关论文
共 19 条
  • [1] Humanized docking system for assembly of targeting drug delivery complexes
    Backer, MV
    Gaynutdinov, TI
    Gorshkova, II
    Crouch, RJ
    Hu, T
    Aloise, R
    Arab, M
    Przekop, K
    Backer, JA
    [J]. JOURNAL OF CONTROLLED RELEASE, 2003, 89 (03) : 499 - 511
  • [2] Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery
    Backer, MV
    Gaynutdinov, TI
    Aloise, R
    Przekop, K
    Backer, JM
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2002, 26 (03) : 455 - 461
  • [3] Molecular vehicles for targeted drug delivery
    Backer, MV
    Aloise, R
    Przekop, K
    Stoletov, K
    Backer, JM
    [J]. BIOCONJUGATE CHEMISTRY, 2002, 13 (03) : 462 - 467
  • [4] Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
    Dubowchik, GM
    Walker, MA
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 83 (02) : 67 - 123
  • [5] Letter to the Editor:: 1H and 15N sequential assignment and solution secondary structure of 15N labelled human pancreatic ribonuclease
    El-Joubary, A
    Bruix, M
    Santoro, J
    Cafaro, V
    Scognamiglio, R
    Di Donato, A
    D'Alessio, G
    Kövér, KE
    Batta, G
    Szilágyi, L
    Rico, M
    [J]. JOURNAL OF BIOMOLECULAR NMR, 1999, 15 (03) : 265 - 266
  • [6] SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling
    Guex, N
    Peitsch, MC
    [J]. ELECTROPHORESIS, 1997, 18 (15) : 2714 - 2723
  • [7] Gupta V, 1999, PROTEINS, V35, P1, DOI 10.1002/(SICI)1097-0134(19990401)35:1<1::AID-PROT1>3.0.CO
  • [8] 2-2
  • [9] KIM JS, 1993, PROTEIN SCI, V2, P348
  • [10] Program DYNAFIT for the analysis of enzyme kinetic data: Application to HIV proteinase
    Kuzmic, P
    [J]. ANALYTICAL BIOCHEMISTRY, 1996, 237 (02) : 260 - 273